

**Vermont Oxford Network**  
**Delivery Room Management Clinical Trial – Web Conference #11**  
**DRM Trial Update and Related Research on Nasal CPAP – The COIN Trial**  
**March 7, 2007**  
**Interest Disclosure & CME Information**

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Vermont and the Vermont Oxford Network. The University of Vermont is accredited by the ACCME to provide continuing medical education for physicians. The University of Vermont designates this educational activity for a maximum of 1.5 AMA PRA Category I Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**How to receive CME credit:**

**SIGN YOUR NAME ON THE SIGN-UP FORM – IT MUST BE LEGIBLE TO RECEIVE CREDIT**

Complete the *Scanner Evaluation Form*, and the *Program Evaluation Form*.

Your feedback is extremely important to us!

Return the *Scanner Evaluation Form* and the *Program Evaluation Form* to your site coordinator at the end of each session.

**Interest Disclosures:**

As an organization accredited by the ACCME to sponsor continuing medical education activities, The University of Vermont is required to disclose any real or apparent conflicts of interest (COE) that any speakers may have related to the content of their presentations.

**No Interests to Disclose:**

♦Karla Ferrelli, BA

♦Martha Grady, RN, MSN

♦Colin Morley, MD

**Interest to Disclose/COI/Bias Resolved\*:**

♦Roger F. Soll, MD – “I have acted as a consultant I have acted as a consultant or received honoraria from the following corporate organizations: Ross Laboratories, Abbott Laboratories, Dey Laboratories, Discovery, Burroughs-Wellcome, Chiesi Pharmaceuticals, Inhibitex, Arizeke. To my knowledge, I hold no stock in any of the corporate entities noted above. I am currently the Vice President of the Vermont Oxford Network and Director of Clinical Trials. In this capacity, I have previously received funds from Beiersdorf Medical to support a trial of emollient ointment in the prevention of nosocomial infection, and from Ross Laboratories to conduct a study of early intubation and surfactant treatment in moderately premature infants. In addition, I receive support from a grant from the NICHD as coordinating editor of the Cochrane Neonatal Collaborative Group.”

**No speakers have indicated they will be discussing the unlabeled use of a commercial product.**

*The University of Vermont requires that each speaker participating in a program designated for AMA Physician's Recognition Award Category 1 credit disclose any financial interest/arrangement or affiliation with a corporate organization that may impact on his/her presentation (i.e. grants, research support, honoraria, member of speakers' bureau, consultant, major stock shareholder, etc.). In addition, the faculty member must disclose when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during the educational activity.*

*\*Having a financial interest or other relationship with a corporate organization, or **discussing an unlabeled use of a commercial product**, may not prevent a speaker from making a presentation. However, the existence of the relationship must be made known to the planning committee prior to the conference, so any possible conflict of interest may be resolved prior to the talk.*